NRXP
Closed
Nrx Pharmaceuticals Inc
3.13
-0.13 (-3.99%)
Last Update: 01 Jul 2025 23:15:00
Yesterday: 3.26
Day's Range: 3.1 - 3.25
Send
sign up or login to leave a comment!
When Written:
0.579
NRX Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that focuses on developing novel therapies for central nervous system (CNS) disorders. The company's lead product candidate, NRX-101, is a nasal spray formulation of ketamine, a well-known anesthetic drug that is being developed for the treatment of major depressive disorder (MDD) and suicidal ideation.
NRX-101 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of MDD and is currently in Phase 2 clinical trials. The company is also developing NRX-102, a long-acting oral formulation of ketamine, for the treatment of MDD and other CNS disorders.
In addition to its ketamine-based product candidates, NRX Pharmaceuticals is also developing NRX-103, a combination of two FDA-approved drugs, d-cycloserine and lurasidone, for the treatment of cognitive impairment associated with schizophrenia.
NRX Pharmaceuticals was founded in 2015 and is headquartered in New York, NY.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
NRX-101 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of MDD and is currently in Phase 2 clinical trials. The company is also developing NRX-102, a long-acting oral formulation of ketamine, for the treatment of MDD and other CNS disorders.
In addition to its ketamine-based product candidates, NRX Pharmaceuticals is also developing NRX-103, a combination of two FDA-approved drugs, d-cycloserine and lurasidone, for the treatment of cognitive impairment associated with schizophrenia.
NRX Pharmaceuticals was founded in 2015 and is headquartered in New York, NY.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








